The role of visfatin in pathogenesis of gestational diabetes (GDM)
Open Access
- 28 September 2018
- journal article
- review article
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 89 (9) , 518-521
Abstract
Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis of GDM. Adipose tissue is an organ involved in production of adipokines, which have various influence on metabolism of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the pathophysiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine mentioned above and GDM, and to clarify its role in the pathophysiology of GDM. Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis of GDM. Adipose tissue is an organ involved in production of adipokines, which have various influence on metabolism of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the pathophysiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine mentioned above and GDM, and to clarify its role in the pathophysiology of GDM.Keywords
This publication has 31 references indexed in Scilit:
- Central visfatin potentiates glucose-stimulated insulin secretion and β-cell mass without increasing serum visfatin levels in diabetic ratsCytokine, 2014
- Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancyArchives of Gynecology and Obstetrics, 2011
- Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic reviewDiabetes/Metabolism Research and Reviews, 2011
- The role of visfatin in the pathogenesis of gestational diabetes mellitusJournal of Endocrinological Investigation, 2011
- New Insights on Glucose Pathophysiology in Gestational Diabetes and Insulin ResistanceCurrent Diabetes Reports, 2010
- Visfatin in gestational diabetes: Serum level and mRNA expression in fat and placental tissueDiabetes Research and Clinical Practice, 2009
- Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimesterJournal of Endocrinological Investigation, 2008
- Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose toleranceDiabetologia, 2007
- The release of the adipocytokine visfatin is regulated by glucose and insulinDiabetologia, 2006
- Gestational Diabetes Mellitus2002